Коморбидности псориаза в детском возрасте

Псориаз — мультифакториальное системное заболевание, характеризующееся избыточным ороговением кожи ввиду нарушения процессов пролиферации и дифференцировки кератиноцитов. Заболевание часто манифестирует в детском возрасте и нередко связано с развитием коморбидных состояний, ряд из которых объединен термином «псориатический марш» (ожирение, метаболический синдром и др.). Течение псориаза и связанных с ним коморбидностей у детей имеет ряд специфических особенностей, обусловливающих актуальность изучения вопросов клинической диагностики и профилактики последних в детском возрасте. В статье резюмированы современные представления о распространенности, особенностях патогенеза и ранней диагностике коморбидных заболеваний у детей с псориазом.

1. Псориаз у детей: клинические рекомендации. Союз педиатров России; 2016. по: https://medi.ru/klinicheskie-rekomendatsii/psoriaz-u-detej_14213. Ссылка активна на 22.10.2020.

2. Wong Y, Nakamizo S, Tan KJ, Kabashima K. An Update on the Role of Adipose Tissues in Psoriasis. Front Immunol. 2019;10:1507. doi: 10.3389/fimmu.2019.01507.

3. Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18(6):797–811. doi: 10.1007/s40257-017-0294-9.

4. Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: 10.1111/pde.13772.

5. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: A systematic review and metaanalysis of observational studies. Nutr Diabetes. 2012;2:e54. doi: 10.1038/nutd.2012.26.

6. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251. doi: 10.1056/nejmoa066886.

7. Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol. 2009;161(2):484–486. doi: 10.1111/j.1365-2133.2009.09276.x.

8. Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176. doi: 10.1001/jamadermatol.2013.1078.

9. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013; 339(6116):172–177. doi: 10.1126/science.1230721.

10. Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity. 2017;47(6):1154–1168. doi: 10.1016%2Fj.immuni.2017.11.009.

11. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells. Nature. 2010;463(7280):540–544. doi: 10.1038/nature08636.

12. Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118. doi: 10.1111/ijd.13699.

13. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–919. doi: 10.1016/j.jaci.2005.02.023.

14. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010; 24(12):1386–1394. doi: 10.1111/j.1468-3083.2010.03647.x

15. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130(7):1785–1796. doi: 10.1038/jid.2010.103.

16. Ommen P, Stjernholm T, Kragstrup T, et al. The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. Br J Dermatol. 2016;174(1):187–90. doi: 10.1111/bjd.13969.

17. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092–1101. doi: 10.1016/j.bbrc.2005.06.202.

18. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9): 5789–5795. doi: 10.4049/jimmunol.174.9.5789.

19. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79. doi: 10.1006/bbrc.1999.0255.

20. Shibata S, Tada Y, Hau CS, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from -T cells. Nat Commun. 2015;6:7687. doi: 10.1038/ncomms8687.

21. Endo Y, Asou HK, Matsugae N, et al. Obesity drives Th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 2015;12(6):1042–1055. doi: 10.1016/j.celrep.2015.07.014.

22. Kanemaru K, Matsuyuki A, Nakamura Y, Fukami K. Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin- 17 and interleukin-22 production in mice. Exp Dermatol. 2015;24(6):436–442. doi: 10.1111/exd.12691.

23. Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal T cells number: A prospective case series study. Br J Dermatol. 2014;171(1): 155–161. doi: 10.1111/bjd.12886.

24. Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38(1):86–88. doi: 10.1016/j.diabet.2011.11.004.

25. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829. doi: 10.1016/j.jaad.2006.08.040.

26. Badaoui A, Tounian P, Mahe E. Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. Arch Pediatr. 2019;26(2):86–94. doi: 10.1016/j.arcped.2018.12.005.

27. Osier E, Wang AS, Tollefson MM, Cordoro KM. Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol. 2017; 153(7):698–704. doi: 10.1001/jamadermatol.2017.0499.

28. Рекомендации по ведению больных с метаболическим синдромом: клинические рекомендации. Союз педиатров России; 2013. Доступно по: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjF28KP8MfsAhXpxIsKHfKSAwkQFjAAegQIBBAC&url=http%3A%2F%2Fwww.gipertonik.ru%2Ffiles%2Frecommendation%2FRecommendations_metabolic_syndrome.doc&usg=AOvVaw0OlaDnVqEqE_s6p37JaUFm. Ссылка активна на 22.10.2020.

29. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015.

30. Goldminz AM, Buzney CD, Kim N, et al. Prevalence of the metabolic syndrome in children with psoriatic disease. Pediatr Dermatol. 2013;30(6):700–705. doi: 10.1111/pde.12218.

31. Tom WL, Playford MP, Admani S, et al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. J Invest Dermatol. 2016;136(1):67–73. doi: 10.1038/jid.2015.385.

32. Al Mutairi N, Alrqobah D, Haji Hussain N. Prevalence of metabolic syndrome in children with moderate to severe psoriasis treated with TNF inhibitors in comparison to conventional agents. Dermatol Ther. 2018;31(1). doi: 10.1111/dth.12566.

33. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi: 10.1016/s0140-6736(05)66378-7.

34. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi: 10.1007/s00403-006-0703-z.

35. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x.

36. Azfar RS, Seminara NM, Shin DB, et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148(9):995–1000. doi: 10.1001/archdermatol.2012.1401.

37. Li W, Han J, Hu FB, et al. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol. 2012;132(2):291–298. doi: 10.1038/jid.2011.319.

38. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735–1741. doi: 10.1001/jama.296.14.1735.

39. Mehta NN, Li K, Szapary P, et al. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med. 2013;11:194. doi: 10.1186/1479-5876-11-194.

40. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol. 2012;147(2):179–187.

41. Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1- dependent monocyte adhesion and transendothelial migration. Circ Res. 2011;108(3):335–343. doi: 10.1161/circresaha.110.237420.

42. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of plateletderived microparticles and soluble P-selectin. J Am Acad Dermatol. 2010;62(4):621–626. doi: 10.1016/j.jaad.2009.06.053.

43. Turonova L, Kubejova K, Vorcakova K, et al. Endothelial Dysfunction in Children with Juvenile Psoriatic Arthritis. Acta Medica (Hradec Kralove). 2018;61(3):79–85. doi: 10.14712/18059694.2018.122.

44. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Am Acad Dermatol. 2020;82(1):161–201. doi: 10.1016/j.jaad.2019.08.049.

45. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110–113. doi: 10.1159/000182256.

46. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271–276. doi: 10.1111/j.1365-2133.2006.07562.x.

47. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi: 10.1111/jdv.13854.

48. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568. doi: 10.1016/j.rdc.2015.07.001.

49. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi: 10.1097/bor.0b013e328348b278.

50. Tosato F, Bucciol G, Pantano G, et al. Lymphocytes subsets reference values in childhood. Cytometry A. 2015;87(1):81–85. doi: https://doi.org/10.1002/cyto.a.22520

51. Decker ML, Gotta V, Wellmann S, Ritz N. Cytokine profiling in healthy children shows association of age with cytokine concentrations. Sci Rep. 2017;7(1):17842. doi: 10.1038/s41598-017-17865-2.

52. Yatsunenko T, Rey FE, Manary MJ, Trehan I. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402): 222–227. doi: 10.1038/nature11053.

53. Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190–197. doi: 10.3899/jrheum.180168.

54. Коротаева Т.В., Корсакова Ю.Л., Логинова Е.Ю. и др. Псориатический артрит. Клинические рекомендации по диагностике и лечению // Современная ревматология. — 2018. — Т. 12. — № 2. — С. 22–35. doi: 10.14412/1996-7012-2018-2-22-35.

55. Helliwell PS. Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting. J Rheumatol. 201;38(3):551–552. doi: 10.3899/jrheum.101119.

56. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an exis ting screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009; 27(3):469–474.

57. Niccoli L, Nannini C, Cassara E, et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis. 2012;15(4):414–418. doi: 10.1111/j.1756-185x.2012.01736.x.

58. Centers for Disease Control and Prevention. What is IBD? Available online: https://www.cdc.gov/ibd/what-is-IBD.htm. Accessed on 25 May, 2020.

59. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–764. doi: 10.1016/j.jhep.2009.04.020.

60. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722–727. doi: 10.1111/ced.12672.

61. Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657.e1–2. doi: 10.1016/j.jaad.2011.11.948.

62. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995–2012. Br J Dermatol. 2013;169(4):734–759. doi: 10.1046/j.1525-1470.2002.00026.x.